|
Affiliation |
Graduate School of Medicine Doctorial Course in Medicine Oncoregulatory Medicine Department of Urology |
|
Date of Birth |
1974 |
NARITA Sintaro
|
|
|
Research Interests 【 display / non-display 】
-
泌尿器癌
-
腹腔鏡手術
-
泌尿器腫瘍
-
腹腔鏡手術
-
robotic surgery
Graduating School 【 display / non-display 】
-
-1999.03
Akita University Faculty of Medicine Graduated
Graduate School 【 display / non-display 】
-
-2004.09
Akita University Graduate School,Division of Medicine Doctor's Course Completed
Campus Career 【 display / non-display 】
-
2020.05-Now
Akita University Graduate School of Medicine Doctorial Course in Medicine Oncoregulatory Medicine Associate Professor
-
2017.01-2020.04
Akita University Hospital Division of Blood Purification Associate Professor
-
2011.01-2016.12
Akita University Hospital Urology Lecturer
Research Achievements 【 display / non-display 】
-
Impact of Age on Treatment Patterns and Outcomes in Patients With Non-Metastatic Castration-Resistant Prostate Cancer.
Hiroki Hagimoto, Shinichi Sakamoto, Kodai Sato, Kazuyoshi Nakamura, Hiroki Kito, Satoshi Fukasawa, Daichi Hino, Yusuke Shiraishi, Kohei Hashimoto, Yuto Matsushita, Shintaro Narita, Jun Miki, Takuma Kato, Ryuji Matsumoto, Toshihiro Saito, Ryotaro Tomida, Takahiro Kimura, Hiroshi Kitamura, Tomohiko Ichikawa, Yoshiyuki Matsui
International journal of urology : official journal of the Japanese Urological Association 2025.12
Research paper (journal)
OBJECTIVES: To evaluate the impact of age on treatment patterns and outcomes in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). METHODS: We conducted a retrospective multicenter analysis of 428 patients with nmCRPC from 25 tertiary centers (2002-2022). Patients were divided into two age groups: < 80 and ≥ 80 years. The outcomes included cancer-specific survival (CSS), overall survival (OS), and progression-free survival (PFS). RESULTS: Among 428 patients (median follow-up, 32.5 months), performance status (PS) 0 was more frequent in < 80 vs. ≥ 80 years (78% vs. 58%, p < 0.001). Use of first-line androgen receptor signaling inhibitors (ARSIs) was similar (58% vs. 59%, p = 0.83) among all, whereas any-line docetaxel use was less common in patients aged ≥ 80 years (33% vs. 9% for < 80 vs. ≥ 80, p < 0.001). Five-year CSS was 76.5% vs. 63.7% (p = 0.002) and five-year OS 73.8% vs. 59.9% (p = 0.006) for < 80 vs. ≥ 80 years, respectively. Time-to-treatment failure was shorter in patients aged ≥ 80 years (p = 0.04). CONCLUSION: Maintaining PS and managing ARSI-related adverse events are essential in older patients with nmCRPC and may preserve their eligibility for chemotherapy and improve their prognosis.
-
Protocol summary of a randomized controlled phase III trial for confirming the superiority of local radiotherapy for prostate cancer patients with high-volume metastasis sensitive to hormonal therapy: the JCOG2011 (HimeRT study).
Naoki Terada, Keiji Nihei, Rihito Aizawa, Shintaro Narita, Takahiro Kojima, Masaki Shiota, Shusuke Akamatsu, Takahiro Kimura, Takahiro Inoue, Mikio Sugimoto, Yuta Sekino, Keita Sasaki, Taro Shibata, Haruhiko Fukuda, Hiroyuki Nishiyama, Hiroshi Kitamura, Takashi Mizowaki
Japanese journal of clinical oncology 2025.10
Research paper (journal)
Local therapy is not considered a standard treatment option for patients with high-volume metastatic prostate cancer. Our research group's previous retrospective study indicated potential benefits of local radiotherapy (LRT) for some high-volume metastatic prostate cancer patients, but prospective studies have yet to confirm these findings. We have thus planned a multicenter, open-label, randomized controlled phase III trial to confirm the efficacy of adding LRT to systemic hormonal therapy with androgen deprivation therapy plus an androgen receptor pathway inhibitor in a population of high-volume metastatic prostate cancer patients for whom the hormonal therapy is effective for 6 months. The primary endpoint is failure-free survival, defined as the time from randomization to prostate-specific antigen progression, radiological progression, clinical progression, or death from any cause. We aim to enroll 360 patients from 56 institutions over a 4-year period. This trial is registered at the Japan Registry of Clinical Trials (study no. jRCT1031220676).
-
Influence of genetic polymorphisms in vascular endothelial-related genes on the clinical outcome of axitinib in patients with metastatic renal cell carcinoma.
Kazuyuki Numakura, Ryoma Igarashi, Makoto Takahashi, Taketoshi Nara, Sohei Kanda, Mitsuru Saito, Shintaro Narita, Takamitsu Inoue, Takenori Niioka, Masatomo Miura, Tomonori Habuchi
Cancer biology & therapy 25 ( 1 ) 2312602 - 2312602 2024.12
Research paper (journal)
OBJECTIVE: Axitinib is an oral multi-target tyrosine kinase inhibitor used for the treatment of renal cell carcinoma (RCC). Because of the severe adverse events (AEs) associated with axitinib, patients often need dose reductions or discontinue its use, highlighting the need for effective biomarkers to assess efficacy and/or AEs. The aim of this study was to investigate the relationship between single nucleotide polymorphisms (SNPs) in genes involved in the pharmacodynamic action of axitinib and clinical prognosis and AEs in metastatic RCC (mRCC) patients. METHODS: This study included 80 mRCC patients treated with first-, second-, or third-line axitinib (5 mg orally twice daily). Clinical parameters and genetic polymorphisms were examined in 75 cases (53 males and 22 females). We assessed three SNPs in each of three candidate genes namely, angiotensin-converting enzyme (ACE), nitric oxide synthase 3 (NOS3), and angiotensin II receptor type 1 (AT1R), all of which are involved in axitinib effects on vascular endothelial function. RESULTS: Axitinib-treated patients carrying the ACE deletion allele suffered more frequently from hand-foot syndrome and a deterioration in kidney function (p = .045 and p = 0.005, respectively) whereas those carrying the NOS3 G allele suffered more frequently from proteinuria and multiple AEs (p = .025 and p = 0.036, respectively). CONCLUSIONS: Our study found that the ACE deletion allele and the NOS3 G allele are associated with increased AEs.
-
Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study.
Takafumi Yanagisawa, Wataru Fukuokaya, Shingo Hatakeyama, Shintaro Narita, Katsuki Muramoto, Kouta Katsumi, Hidetsugu Takahashi, Fumihiko Urabe, Keiichiro Mori, Kojiro Tashiro, Kosuke Iwatani, Tatsuya Shimomura, Tomonori Habuchi, Takahiro Kimura
The Prostate e24813 2024.10
Research paper (journal)
PURPOSE: We aimed to assess the differential efficacy and safety of androgen receptor pathway inhibitors (ARPI), such as abiraterone, enzalutamide, and apalutamide, in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in a real-world practice setting. METHODS: We retrospectively reviewed the records of consequent 668 patients with mHSPC treated with ARPI plus androgen deprivation therapy between September 2015 and December 2023. Based on the LATITUDE criteria, the comparison among abiraterone, enzalutamide, and apalutamide was exclusively conducted in high-risk patients. Prostate-specific antigen (PSA) responses such as the achievement of 95% and 99% PSA decline, overall survival (OS), cancer-specific survival (CSS), time to castration-resistant prostate cancer (CRPC), and the incidence of adverse events (AEs) were compared. All two-group comparisons relied on propensity score matching (PSM) to minimize the effect on possible confounders. RESULTS: In total, 297 patients with high-risk mHSPC treated with abiraterone, 127 with enzalutamide, and 142 with apalutamide were compared. There were no differences in time to CRPC (p = 0.13), OS (p = 0.7), and CSS (p = 0.5) among the three ARPIs. No differences were observed in the achievement rates for 95% PSA decline at 3 months among the three ARPIs, while abiraterone was significantly better in 99% PSA decline achievement compared to apalutamide (72% vs. 57%, p = 0.003). The aforementioned oncologic outcomes were sustained even when performing PSM analyzes. Although skin rash for APA (34%) was the highest incidence of AEs, there were no differences in the rates of severe AEs across the three ARPIs. Enzalutamide resulted in the lowest treatment discontinuation rates (10%) other than disease progression compared to the other regimens. CONCLUSIONS: Abiraterone, enzalutamide, and apalutamide have comparable oncologic outcomes in terms of OS, CSS, and time to CRPC in patients with high-risk mHSPC. Our data on differential treatment discontinuation rates, PSA response, and AE profiles can help guide clinical decision-making.
-
Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvement.
Tokiyoshi Tanegashima, Masaki Shiota, Takahiro Kimura, Dai Takamatsu, Yoshiyuki Matsui, Akira Yokomizo, Ryoichi Saito, Shuichi Morizane, Makito Miyake, Masakazu Tsutsumi, Yoshiyuki Yamamoto, Kojiro Tashiro, Ryotaro Tomida, Kohei Edamura, Shintaro Narita, Takahiro Yamaguchi, Takashi Kasahara, Kohei Hashimoto, Masashi Kato, Takayuki Yoshino, Shusuke Akamatsu, Akihiro Matsukawa, Tomoyuki Kaneko, Ryuji Matsumoto, Akira Joraku, Manabu Kato, Toshihiro Saito, Takuma Kato, Shuichi Tatarano, Shinichi Sakamoto, Hidenori Kanno, Naoki Terada, Naotaka Nishiyama, Hiroshi Kitamura, Masatoshi Eto
International journal of clinical oncology 29 ( 10 ) 1586 - 1593 2024.10
Research paper (journal)
BACKGROUND: The therapeutic role of pelvic lymph node dissection (PLND) during radical prostatectomy (RP) for prostate cancer is not established. In clinical practice, PLND is primarily performed in cases of high-risk prostate cancer. The detection of lymph node metastasis plays a crucial role in determining the need for subsequent treatments. This study aims to evaluate the prognosis of prostate cancer patients with lymph node involvement (LNI) by stratifying them based on postoperative prostate-specific antigen (PSA) levels to identify biomarkers that can guide postoperative treatment strategies. METHODS: Analysis was conducted on 383 patients, selected from 572 initially eligible, who underwent RP with LNI across 33 Japanese Urological Oncology Group institutions from 2006 to 2019. Patients were grouped according to postoperative PSA levels and salvage treatments received. Follow-up focused on castration resistance-free survival (CRFS), metastasis-free survival (MFS), and overall survival (OS). RESULTS: In the persistent PSA group (PSA ≥ 0.1 ng/mL), CRFS and MFS were significantly shorter compared to the non-persistent PSA group (PSA < 0.1 ng/mL), and there was a tendency for shorter OS. In the persistent PSA group, patients with postoperative PSA values above the median (PSA ≥ 0.52 ng/mL) showed shorter CRFS and MFS. Furthermore, in the PSA ≥ 0.52 group, androgen deprivation therapy (ADT) plus radiotherapy (RT) combination had prolonged CRFS and MFS compared with ADT alone. CONCLUSIONS: This study provides valuable insights into stratifying patients based on postoperative PSA levels to tailor postoperative treatment strategies, potentially improving the prognosis of prostate cancer patients with LNI.
-
前立腺癌におけるNLRP3インフラマソームと病期分類の関連(Association between NLRP3 Inflammasome and Tumor-Node-Metastasis Staging in Prostate Cancer)
宮内 隼弥, 成田 伸太郎, 齋木 由利子, 工藤 幸紹, 堀井 明, 福重 真一, 羽渕 友則, 南條 博, 後藤 明輝
日本病理学会会誌 ( (一社)日本病理学会 ) 114 ( 1 ) 371 - 371 2025.03
-
FOUR CASES OF BLADDER CANCER IN YOUNG PATIENTS WITH SEVERE MOTOR AND INTELLECTUAL DISABILITIES
奈良健平, 沼倉一幸, 菊池茜恵, 関根悠哉, 武藤弓奈, 小林瑞貴, 嘉島相輝, 山本竜平, 齋藤満, 成田伸太郎, 羽渕友則
泌尿器科紀要 70 ( 8 ) 2024
-
高リスク限局性前立腺癌に対する術前化学内分泌療法の臨床病理学的検討
蘇武 竜太, 成田 伸太郎, 小林 瑞貴, 嘉島 相輝, 山本 竜平, 奈良 健平, 沼倉 一幸, 齋藤 満, 南條 博, 羽渕 友則
日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 ) 61回 O34 - 2 2023.10
-
ラード食は腸内細菌叢変化を介して腫瘍浸潤制御性T細胞を誘導し前立腺癌進展を促進する(Lard diet accelerates prostate cancer progression through tumor infiltrating Treg recruitment by gut microbial changes)
佐藤 博美, 成田 伸太郎, 高橋 佳子, 石田 雅宣, 小林 瑞貴, 嘉島 相輝, 山本 竜平, 奈良 健平, 黄 明国, 沼倉 一幸, 齋藤 満, 吉岡 年明, 堂前 直, 羽渕 友則
日本癌学会総会記事 ( (一社)日本癌学会 ) 82回 864 - 864 2023.09
-
BRAF V600E変異は副腎腫瘍からのコルチゾール産生を亢進する(BRAF V600E mutation promoted excess of cortisol secretion in adrenal cortical adenoma)
沼倉 一幸, 武藤 弓奈, 杉山 志子, 小林 瑞貴, 関根 悠哉, 嘉島 相輝, 山本 竜平, 奈良 健平, 黄 明国, 齋藤 満, 成田 伸太郎, 西本 紘嗣郎, 羽渕 友則
日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 110回 AOP08 - 03 2023.04
◆Original paper【 display / non-display 】
◆Other【 display / non-display 】
Academic Awards Received 【 display / non-display 】
-
Best Presentation Award of the ACRLS 2022
2022.12 Asian-Pacific Congress of Robotic Laparoscopic Surgery Best Presentation Award of the ACRLS 2022
Winner： Shintaro Narita
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
The role of FABP4 on HFD-mediated prostate tumor progression in TRAMP mice
Grant-in-Aid for Scientific Research(C)
Project Year： 2024.04 - 2027.03
-
Grant-in-Aid for Scientific Research(C)
Project Year： 2021.04 - 2025.03
-
Establishment of novel therapeutic system for renal cell carcinoma by pahrmacogenomics and transcriptomics
Grant-in-Aid for Scientific Research(C)
Project Year： 2015.04 - 2018.03 Investigator(s): Tsuchiya Norihiko
-
Diet-induced macrophage inhibitory cytokine 1 and prostate cancer progression.
Grant-in-Aid for Scientific Research(C)
Project Year： 2012.04 - 2015.03 Investigator(s): HUANG Mingguo, NARITA Shintaro, TSUCHIYA Norihiko
-
Identification of molecules involved in progression of prostate cancer and construction of risk prediction model using SNP array
Grant-in-Aid for Scientific Research(C)
Project Year： 2012.04 - 2015.03 Investigator(s): TSUCHIYA Norihiko, HABUCHI Tomonori, NARITA Shintaro
Presentations 【 display / non-display 】
-
Complications of robot-assisted nephroureterectomy and their management
Japanese Journal of Endourology and Robotics 2025 - 2025 Japanese Society of Endourology and Robotics
<p> April 2022, robot-assisted nephroureterectomy (RANU) was approved for insurance coverage in Japan. Consequently, the number of facilities performing the procedure is gradually increasing. We compared the perioperative outcomes between patients with upper tract urothelial carcinoma treated with RANU (the RANU group, 19 cases) and conventional laparoscopic surgery (the CLS group, 21 cases) at the Department of Urology, Akita University Hospital. In the CLS group, estimated blood loss was significantly higher, with two cases requiring blood transfusion. Although the frequency of lymph node dissection was similar between the groups, the mean number of lymph nodes removed was higher in the RANU group. Further, although there was no significant difference in the overall incidence of perioperative complications based on the Clavien-Dindo classification grading system, chylous ascites was more frequent in the RANU group. Considering the possibility of incomplete lymphatic vessel sealing during lymph node dissection in RANU, we believe that frequent clipping and the proactive use of sealing devices are essential to ensure effective lymphatic control and reduce complication like chylous ascites.</p>
-
Four Cases of Bladder Cancer in Young Patients with Severe Motor and Intellectual Disabilities
NARA Taketoshi, NUMAKURA Kazuyuki, KIKUCHI Akane, SEKINE Yuya, MUTO Yumina, KOBAYASHI Mizuki, KASHIMA Soki, YAMAMOTO Ryohei, SAITO Mitsuru, NARITA Shintaro, HABUCHI Tomonori
2024.08 - 2024.08
-
Japanese Journal of Endourology 2021 - 2021 Japanese Society of Endourology and Robotics
<p><b>Purpose :</b> We examined whether suturing renorrhaphy increased the parenchymal reduction volume by CT in robot-assisted partial nephrectomy (RAPN).</p><p><b>Materials and Method :</b> We analyzed 69 patients with a renal mass <4 cm in diameter who underwent RAPN between November 2013 and November 2018 at Akita University Hospital. The data of 26 patients who underwent suturing renorrhaphy and those of 43 patients who underwent medullary hemostatic suturing alone were retrospectively compared.</p><p><b>Results :</b> The tumor diameter and RENAL score were not significantly different between the groups. The median operative time, warm ischemic time, and blood loss were not significantly different between the groups. Also, the median parenchymal reduction volume, decreasing rate of eGFR, and incidence rate of high-grade postoperative complications were not significantly different between the groups.</p><p><b>Conclusion :</b> The addition of suturing renorrhaphy to RAPN neither significantly increased the parenchymal reduction volume nor significantly decreased the kidney function when compared with the non-renorrhaphy technique.</p>